Eupraxia Pharmaceuticals Inc
TSX:EPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Golden Star Enterprises Ltd
OTC:GSPT
|
US |
|
Eguana Technologies Inc
XTSX:EGT
|
CA |
|
Indo Tambangraya Megah Tbk PT
OTC:ITAYY
|
ID |
|
F
|
Fortune Oriental Co Ltd
TWSE:2491
|
TW |
|
Access-Power & Co Inc
OTC:ACCR
|
US |
|
H
|
Hybrid Financial Services Ltd
BSE:500262
|
IN |
|
N
|
Nivika Fastigheter AB (publ)
STO:NIVI B
|
SE |
|
China Telecom Corp Ltd
SSE:601728
|
CN |
|
I
|
Iceco Inc
TSE:7698
|
JP |
|
UT Group Co Ltd
TSE:2146
|
JP |
|
Stanley Black & Decker Inc
NYSE:SWK
|
US |
|
I
|
Invincible Investment Corp
TSE:8963
|
JP |
|
Terasaki Electric Co Ltd
TSE:6637
|
JP |
|
M
|
MAG Holdings Berhad
KLSE:MAGNUM
|
MY |
|
BigBear.ai Holdings Inc
NYSE:BBAI
|
US |
|
Century Casinos Inc
NASDAQ:CNTY
|
US |
|
Shanghai Highly Group Co Ltd
SSE:600619
|
CN |
|
Realty Income Corp
NYSE:O
|
US |
|
L
|
Leoni AG
XBER:LEO
|
DE |
Eupraxia Pharmaceuticals Inc
Research & Development
Eupraxia Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Research & Development
-CA$19m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-86%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Research & Development
-CA$11.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$32.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$300.9m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-35%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Research & Development
-$94.5m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eupraxia Pharmaceuticals Inc
Glance View
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
See Also
What is Eupraxia Pharmaceuticals Inc's Research & Development?
Research & Development
-19m
CAD
Based on the financial report for Dec 31, 2025, Eupraxia Pharmaceuticals Inc's Research & Development amounts to -19m CAD.
What is Eupraxia Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-86%
Over the last year, the Research & Development growth was -28%. The average annual Research & Development growth rates for Eupraxia Pharmaceuticals Inc have been -3% over the past three years , -86% over the past five years .
